First, although the current study illustrates that geriatric mouse induction can be a better model for NASH, the model needs some NASH clinical drugs for further validation, such as GLP1R agonists [18], THR-β agonists [19] and FGF21 analogs [42]. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.